Eng Leng is a senior partner in our Corporate practice. He leads and specialises in mergers and acquisitions and corporate work, and runs an active practice in domestic, regional and cross-border private and public mergers and acquisitions, privatisations, takeovers, corporate commercial, corporate finance, corporate restructurings, securities law, private equity and general corporate law work. His breadth and depth of experience and expertise extends across several industries and sectors including financial institutions, healthcare and technology.
Eng Leng's work in public and private mergers and acquisitions and corporate and commercial transactions includes acting for both the sell-side and the buy-side (bilateral as well as by way of auction). He advises on and is also active in schemes of arrangement, investments, joint ventures, shareholder arrangements, and listed companies work. Clients include domestic and international corporates (listed and unlisted), private equity firms and family offices.
He is also frequently consulted for his expertise in corporate and commercial strategies relating to such transactions.
Eng Leng graduated from National University of Singapore with LLB (Hons) and LLM.
- E-mail: engleng.ng@dentons.com
- Lawyer Page: https://dentons.rodyk.com/en/engleng-ng
- 80 Raffles Place
#33-00 UOB Plaza One
Singapore 048624
Singapore
- English
- Mandarin
- United Kingdom, Admitted to the Roll of Solicitors, England and Wales, 2001
- Singapore, Advocate & Solicitor, 1990
- Dentons Rodyk & Davidson LLP - Senior Partner
31 The Best Lawyers in Singapore™ awards
- Mergers and Acquisitions Law
- Independent Director (Board and Audit and Risk Committee Member), A-iTrust
- Independent Director (Board and Remuneration and Audit Committee Member), Hyphens Pharma International Limited
- Technology
- Corporate
- Mergers and Acquisitions
- Chambers Asia Pacific: Recognized as Leading Individual for Corporate/M&A: Domestic, 2012 – 2019
- Chambers Global: Recognized as Leading Individual for Corporate/M&A: Domestic, 2012 – 2019
- “Ng Eng Leng acts across the full spectrum of corporate and M&A work, winning praise from clients and from peers for being ‘very experienced.’ He has a notable ability for handling work involving Malaysia and Japan.” – Chambers Asia Pacific, Corporate/M&A: Domestic - Singapore, 2019
- “Ng Eng Leng is praised by sources for his sound commercial awareness.” – Chambers Asia Pacific, Global, Corporate/M&A, 2018
- Best Lawyers: Recognized for Corporate Law and Mergers and Acquisitions in Singapore, 2014 – 2020
- In-House Community 2016: Commended External Counsel of the Year
- IFLR1000: Highly Regarded (Leading Lawyer) for M&A, 2017 – 2019
- IFLR1000: Highly Regarded (Leading Lawyer) for Mergers and Acquisitions and Restructuring, 2015
- “Leading corporate partner Ng Eng Leng acted for the shareholders of Ramba Energy in the voluntary conditional cash partial offer by Sugih Energy to acquire 51% of the issued ordinary shares in the capital of Ramba Energy, listed on the Mainboard of the Singapore stock exchange.” – Asialaw, 2015
- “Leading corporate partner Ng Eng Leng has been acting for Parkway HK holdings in a significant joint venture with NWS Holdings in Hong Kong ...” – Asialaw 2014
- Asialaw: Recognized as a Leading Lawyer for Corporate/M&A in Singapore, 2014, 2017 – 2018
- “Ng [Eng Leng] is acting for Parkway HK Holdings, a subsidiary of Malaysia-based IHH Healthcare, in its joint venture with a subsidiary of Hong Kong-listed NWS Holdings, for the development, construction, management and operation of a hospital in Hong Kong with a total estimated project cost of HK$5 billion ($644 million).” – IFLR1000, 2014
- ILO Client Choice Awards 2014 for M&A in Singapore
- ALB Client Choice Hot 75 - 2013
- “Ng Eng Leng [is] recommended.” – The Legal 500 Asia Pacific, 2013
- Who's Who Legal: Recognized for Mergers and Acquisitions, Singapore, 2008
Your browser is not fully compatible with our automatic printer friendly formatting.
Please use the print button to print this profile page.